It has been demonstrated that ovarian cancer cells treated with anti-FRα single-chain intrabodies exhibit decreased cellular adhesion, decreased anchorage-independent growth, and suppressed cell division [105]. This evidence concerns the gene FOLR1 and ovarian carcinoma.